

# Synthesis of (±)-4-Substituted Pipecolinic Acids from 4-Alkylpyridines

Abdesslame Nazih<sup>a</sup>, Marie-Reine Schneider<sup>b</sup> and André Mann<sup>\*b</sup>

<sup>a</sup> Université Louis Pasteur-CNRS, Faculté de chimie, BP 296, F-67008 Strasbourg, France


<sup>b</sup> Laboratoire de Pharmacochimie de la Communication Cellulaire - ERS 655 Faculté de Pharmacie, 74, route du Rhin, 67401 Illkirch Cedex, France.

Fax (33) 3 88 67 68 86 ; E-mail André. mann@pharma. u-strasbg.fr

Received 6 October 1998

**Abstract:** Starting from various 4-alkylpyridines, the phenyldimethylsilyl group was introduced using their 1-acylpyridinium salts and its oxidative unmasking afforded the corresponding pipecolinic acids.

Pipecolinic acid and derivatives have been widely used as cyclic homologues of proline in numerous peptidomimetics.<sup>1</sup> In this context several syntheses of 4-substituted pipecolinic acids have been performed.<sup>2-11</sup> In this letter, we report a new approach to pipecolinic acids starting from commercially available 4-alkylpyridines.




**Scheme 1.** (i) Me<sub>2</sub>PhSiCH<sub>2</sub>MgCl, ClCO<sub>2</sub>R<sup>1</sup>; (ii) H<sub>2</sub>, PtO<sub>2</sub>, AcOEt; (iii) Hg(CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub> (1.2 eq), AcOOH/AcOH, RT; (iv) RuCl<sub>3</sub>/NaIO<sub>4</sub>, Ref.15; (v) HCl (6 N), reflux

As outlined in Scheme 1, our approach involved the nucleophilic addition of [(phenyldimethylsilyl)methyl]magnesium chloride to the 1-acyl-4-substituted pyridinium salts and subsequent reduction of the dihydropyridines (**1a-c**) which afforded the piperidines (**2a-c**). The interconversion of the phenyldimethylsilyl group into the primary alcohol yielded the piperidinols (**3b-c**) and subsequent oxidation, the N-protected pipecolinic acids (**4b-c**). A final hydrolytic cleavage afforded the pipecolinic acids (**5b-c**). This sequence needs some comments.

The addition of Ph(Me)<sub>2</sub>SiCH<sub>2</sub>MgCl to 4-alkylpyridines, without precedent in the literature, was effective using the *in situ* generation of the corresponding N-acyliminium ion.<sup>12</sup> After acidic hydrolysis, and chromatographic purification, 1,2-dihydropyridines (**1a-c**) were obtained in good yields.<sup>13</sup> The hydrogenation of the 1,2-dihydropyridines afforded the piperidines (**2a-c**): compounds **2a** and **2c** were isolated as the *cis* diastereomers. Whereas compound **2b** was obtained as a diastereomeric mixture (*cis* / *trans* : 7 / 3), as evidenced by the integration of the corresponding methyl peaks in the <sup>1</sup>H-NMR spectra; the *cis* isomer (**2b-cis**) could be obtained in pure form after

chromatography.<sup>13</sup> Among the experimented oxidative methods to transform the phenyldimethylsilyl into the hydroxymethylene group,<sup>14</sup> we found that the mixture : (CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub>Hg (1.2 eq), AcOOH (20 eq), AcOH was the best choice and represented an improvement of the already existing methods. Indeed, the reaction was completed within 1 h at room temperature and the N-protected piperidinols **3b-cis**<sup>13</sup> and **3c** were obtained in 71% and 76% yield, respectively. The oxidation of **3b-cis** and **3c** under Sharpless conditions<sup>15</sup> afforded the N-protected pipecolinic acids **4b** (69%) and **4c** (81%) which could be readily deprotected with HCl 6 N to (±)-(*cis*)-4-methyl- and (±)-(*cis*)-4-phenylpipecolinic acid respectively **5b**<sup>5,13</sup> and **5c**<sup>13</sup> in quantitative yields.

The presence of the phenyl rest in **4c** gives us the opportunity to extend the scope of our procedure in preparing the (±)-*cis*-2,4-piperidinedicarboxylic acid, a selective NMDA agonist,<sup>16</sup> in the following way. Compound **4c** was treated with an ethereal solution of diazomethane at 0°C and submitted to the Sharpless conditions,<sup>15</sup> adapted for oxidative cleavage of an aromatic ring, to yield **6c** in moderate yields. Finally the rigid glutamic analogue **7c** was obtained as hydrochloride under hydrolytic conditions (Scheme 2).



**Scheme 2.** (i) CH<sub>2</sub>N<sub>2</sub>, Et<sub>2</sub>O; (ii) RuCl<sub>3</sub>/NaIO<sub>4</sub>, Ref.15; (iii) HCl (6 N) reflux

In summary, we have developed a general method for the synthesis of (±)-(*cis*)-4-substituted pipecolinic acids starting from 4-substituted pyridines. This method takes advantage of the nucleophilic addition of [(phenyldimethylsilyl)methyl]magnesium chloride to pyridinium salts and of oxidative removal of the phenyldimethylsilyl moiety. We are currently exploring the scope of this method for the synthesis of other heterocyclic compounds.

**Acknowledgment.** We thank Dr. D. Heissler for making available laboratory facilities at the Unité Mixte de Recherche 7509.

## References and Notes

- Giannis, A.; Kolter, T. *Angew. Chem. Int. Ed. Engl.* **1993**, *32*, 1244-1267.
- Bannett, F.; Patel, N. M.; Girijavallabhan, V. M.; Ganguly, A. K. *Synlett* **1993**, 703-704.
- Genin, M. J.; Gleason, W. B.; Johnson, R. L. *J. Org. Chem.* **1993**, *58*, 860-866.
- Smith III, A. B.; Condon, S. M.; McCauley, J. A. *Acc. Chem. Res.* **1998**, *31*, 35-38.
- Shuman, R. T.; Ornstein, P. L.; Paschal, J. W.; Gesellchen, P. D. *J. Org. Chem.* **1990**, *55*, 738-741.

- (6) Bailey, C. P. D.; Brown, G. R.; Korber, F.; Reed, A.; Wilson, R. D. *Tetrahedron Asymmetry* **1991**, 2, 1263-1282.
- (7) Agami, C.; Couty, F.; Poursoulis, M.; Vaissermann, J. *Tetrahedron* **1992**, 48, 431-442.
- (8) Ornstein, P. L.; Melikian, A.; Martinelli, M. J. *Tetrahedron Lett.* **1994**, 35, 5759-5762.
- (9) Jackson, R. F. W.; Turner, D.; Block, M. H. *Synlett* **1997**, 7 789-790.
- (10) Agami, C.; Bihan, D.; Morgentin, R.; Puchotkadouri, C. *Synlett* **1997**, 7, 799-800.
- (11) Makra, G. M.; Marshall, G. R. *Tetrahedron Lett.* **1997**, 38, 5069-5072.
- (12) Comins, D. L.; Mantlo, N. B. *J. Org. Chem.* **1985**, 50, 4410-4411.
- (13) Experimental procedures and physical data:

**1b** [(Phenyldimethylsilyl)methyl]-magnesium chloride, prepared from chloromethyl-dimethylphenylsilane (3 ml, 16.63 mmol) and magnesium (424 mg, 17.46 mmol) in ether (17 ml), was added to a solution of 4-picoline (1.47 ml, 15.12 mmol) in THF (15 ml) at -20°C. Then a solution of ethyl chloroformate in THF (2 ml) was added and the mixture was left to reach 0°C. After quenching with 5% HCl, the mixture was extracted with ether (2x30 ml), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by chromatography on silica gel (5% ether in hexane) to afford 4.31 g (90%) of dihydropyridine **1b** as a colorless oil.

<sup>1</sup>H NMR [200 MHz, CDCl<sub>3</sub>] : δ 7.55 - 7.35 (m, 5 H), 6.68 and 6.52 (2d, J = 7.5 Hz and 7.7 Hz, 1H), 5.20 - 5.00 (m, 2 H), 4.90 - 4.70 (m, 1 H), 4.16 (m, 2 H), 1.63 (s, 3H), 1.50 - 0.85 (m, 2 H), 1.27 (t, J = 7.1 Hz, 3 H), 0.34 and 0.32 (2 s, 6 H).

**2b-cis** : A solution of dihydropyridine **1b** (3 g, 9.51 mmol) in ethyl acetate (95 ml), was hydrogenated in the presence of PtO<sub>2</sub>. After stirring for 6 h, the mixture was filtered over celite and concentrated in vacuo. The residue was purified by chromatography on silica gel (80% CH<sub>2</sub>Cl<sub>2</sub> in hexane) to afford 2.83 g (93%) of **2b** as a mixture of diastereomers (*cis* / *trans* : 7/3). A second purification by chromatography yielded 1.55 g (53%) of pure **2b-cis**.

<sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) : δ 7.55 - 7.33 (m, 5 H), 5.50 (m, 0.3 H), 4.07 (q, J = 7.1 Hz, 2 H), 4.13 - 3.93 (m, 1 H), 3.69 (ddd, J = 2.8 Hz, 7 Hz, and 13.6 Hz, 0.7 H), 3.04 (ddd, J = 6 Hz, 10.1 Hz and 16.2 Hz, 0.7 H), 2.82 (dt, J = 6.3 Hz, 0.3 H), 1.9 - 1.48 (m, 2 H), 1.45 - 1.00 (m, 5 H), 1.22 and 1.21 (2 t, J = 7.1 Hz, 3 H), 0.91 and 0.79 (2 d, J = 6.7 Hz and 6.3 Hz, 3 H), 0.32, 0.31 and 0.29 (3 s, 6 H). Anal. Calcd for C<sub>18</sub>H<sub>29</sub>NO<sub>2</sub>Si : C, 67.66 %; H, 9.15 %; N, 4.38 %. Found : C, 67.55%; H, 9.33%; N, 4.35%.

**3b-cis** : Mercuric trifluoroacetate (294 mg, 0.69 mmol) was added to a solution of **2b-cis** (200 mg, 0.63 mmol) in peracetic acid (2.65 ml, 12.6 mmol) and acetic acid (2.6 ml). After 1 h of stirring at

room temperature, ether (50 ml) was added and the ether solution washed with Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (20%), water, NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by chromatography on silica gel (25% AcOEt in Hexane) to afford 89 mg (71%) of piperidinol **3b-cis** as a colorless oil. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) : δ 4.12 (q, J = 7.1 Hz, 2 H), 3.86 - 3.74 (m, 3 H), 3.45 (m, 3 H), 3.08 (m, 1 H), 1.76 - 1.55 (m, 3 H), 1.26 (t, 3 H, J = 7.1 Hz), 1.35 - 1.0 (m, 2 H), 0.95 (d, 3 H, J = 6.2 Hz).

**4b-cis** : RuCl<sub>3</sub>·3H<sub>2</sub>O (4 mg) was added to a solution of piperidinol **3b-cis** (80 mg, 0.40 mmol) and NaIO<sub>4</sub> (350 mg, 1.64 mmol) in H<sub>2</sub>O (2.4 ml), CCl<sub>4</sub> (1.6 ml) and CH<sub>3</sub>CN (1.6 ml). After stirring at room temperature for 4 h, ether (40 ml) and H<sub>2</sub>O (10 ml) was added, the organic layer were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by chromatography on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford 59 mg (69%) of compound **4b-cis** as a colorless oil.

<sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) : δ 9.91 (brs, 1H), 4.48 (t, 1 H, 5.9 Hz), 4.1 (q, 2 H, J = 7.1 Hz), 3.8 - 3.55 (m, 1 H), 3.5 - 3.25 (m, 1 H), 2.15 - 1.6 (m, 4 H), 1.45 - 1.15 (m, 1 H), 1.24 (t, 3 H, J = 7.1 Hz), 1.02 (d, 3 H, J = 6.3 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) : δ 178, 157, 62, 54, 39, 33, 31, 26, 19, 15.

**5b-cis** : A solution of **4b-cis** (44 mg, 0.2 mmol) in 6 N HCl (2 ml) was refluxed for 4h. The mixture was then cooled and concentrated in vacuo. The resulting solid product was collected and washed with ether to afford 36 mg (100%) of **5b-cis** without further purification.

F = 257 - 259°C. <sup>1</sup>H NMR (200 MHz, D<sub>2</sub>O) : δ 3.71 (dd, J = 12.7 Hz and 3.2 Hz, 1 H), 3.32 (dq, J = 12.8 Hz and 2.3 Hz, 1 H), 2.87 (td, J = 13.0 Hz and 2.8 Hz, 1 H), 2.15 (dq, J = 13.8 Hz and 2.4 Hz, 1H), 1.85 - 1.5 (m, 2 H), 1.3 - 1.0 (m, 2 H), 0.85 (d, J = 6.4 Hz, 3 H).

Compound **5c** : F = 252-254°C. <sup>1</sup>H NMR (200 MHz, D<sub>2</sub>O) δ 7.28-7.10 (m, 5 H), 3.85 (dd, J = 12.7 Hz and 3.2 Hz, 1H), 3.43 (dq, J = 13.0 Hz and 2.3 Hz, 1H), 3.01 (td, 13.0 Hz and 3.2Hz, 1 H), 2.85 (tt, J = 12.3 Hz, 3.7 Hz, 1 H), 2.32 (dq, 14.1 Hz and 1.9 Hz) 1H), 1.92 (m, 1 H), 1.81-1.58 (m, 2 H). <sup>13</sup>C NMR (50 MHz, D<sub>2</sub>O) δ 171, 142.7, 128.1, 126.3, 125.9, 56.9, 42.9, 38.6, 32.0, 27.7. MS (FAB) (C<sub>12</sub>H<sub>15</sub>NO<sub>2</sub>) : 206 (MH<sup>+</sup>).

**7c-cis** : <sup>1</sup>H NMR (200 MHz, D<sub>2</sub>O) : δ 3.75 (dd, J = 3.2 Hz and 12.7 Hz, 1 H), 3.36 (dq, J = 2.3 Hz and 13.2 Hz, 1 H), 2.86 (dt, J = 3.2 Hz and 13.2 Hz, 1 H), 2.58 (td, J = 3.5 Hz and 12.3 Hz, 1H), 2.40 (m, 1 H), 2.02 (m, 1 H), 1.70 - 1.50 (m, 2 H).

- (14) Fleming, I.; Barbero, A.; Walter, D. *Chem. Rev.* **1997**, 97, 2063-2192.
- (15) Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. *J. Org. Chem.* **1981**, 46, 3936-3938.
- (16) Davies, J.; Evans, R. H.; Francis, A. I.; Jonas, A. W.; Smith, D. A. S.; Watkins, J. C. *Neurosci Res.* **1982**, 7, 1119-1124.